China's Sinovac Biotech starts Phase III trials of its potential COVID-19 vaccine

China’s leing provider of biopharmaceutical products, Sivac Biotech Ltd anunced on July 6 that it was entering phase III clinical trials sponsored by Instituto Butantan, Brazil, to test  efficacy of its experimental COVID-19 vaccine. As one of three pharmaceutical companies to reach  late sts of trials, Sivac said it will recruit over 9,000 healthcare professionals to speed up process to invent potential cure for COVID-19, as per reports.  

In collaboration with Butantan, a leing Brazilian producer of immubiological products and vaccines, Sivac has been given approval to run widescale trials by  Brazilian National Regulatory ncy, Anvisa. human trials aim to be pivotal for licensure of product as Anvisa alrey reviewed  manufacturing and clinical information of  coronavirus vaccines. According to reports, Anvisa conducted  highest standards review of vaccines as it is a member of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (“ICH”). Furr, company is also prequalified as a fully functional regulatory ncy for World Health Organization (WHO).  

In as many as twelve clinical sites located in several states in Brazil, company will start trials basis ethical approval in each clinical site. Director of Instituto Butantan, Dr. Dimas Covas said, “ phase III clinical trial approval is a demonstration that  Sivac and Butantan partnership is an efficient collaboration to move forward offering hope to save lives worldwide.” Furr, Chairman, President and CEO of Sivac Weidong Yin ded, “We are pleased to vance to Phase III trials with Butantan, which will allow us one step furr to our commitment to developing vaccines for global use and to our mission of supplying vaccines to eliminate human diseases.” 

Re: COVID-19: NIH And DBT To Meet This Week; Review On Vaccine Candidates Likely

Re: Aug 15 Target For COVID-19 Vaccine Launch 'unfeasible': Indian Acemy Of Sciences

Vaccine named ‘CORONAVAC’

Earlier, on January 28th, 2020, company started manufacturing of vaccine in early sts against COVID-19 with name ‘CoronaVac’. company published progress, methodology and results of clinical trial in  peer-reviewed acemic journal Science. In April, National Medical Products ministration (“NMPA”) granted vaccine approval to conduct phase I and II clinical trials in Jiangsu Province, China, as per reports. Sivac has partnered with several companies for phase III efficacy studies outside China.  

Re: TMC Slams ICMR's Mid-August Covid Vaccine Deline; Says It's For PM Modi's I-Day Speech

Re: US FDA Chief Refuses To Back Trump's 'year-end' Coronavirus Vaccine Claim